Innovation Showcase - Presenting Companies
With three weeks until the Start Codon 2024 Innovation Showcase, we're shining a spotlight on our presenting companies.
Awen Oncology - Presenter: CEO/Founder - Ramsay McFarlane
Focused on developing a breakthrough range of anti-cancer drugs, the Company's innovative platform homes in on previously untargeted human developmental genes that, while dormant in healthy tissues, behave unexpectedly in the early stages and progression of cancer.
Awen Oncology was spun out of Bangor University and Cardiff University and recently closed its first major funding round, bringing its total funds raised to over £1 million. You can read more about its investment here: https://rb.gy/7qk0rb
Emm - Presenter: CEO/Founder - Jenny Button
The start-up whose mission is to empower individuals to change their quality of life by inherently understanding their health through technology and specialist knowledge.
Less than 2.5% of publicly funded research is dedicated solely to reproductive health, yet 1 in 3 women will suffer from a reproductive or gynaecological health problem.
Clinical baseline data is key for tracking reproductive health, but neither consumers nor clinicians have the tools to accurately measure this.
Founded by CEO, Jenny Button, Emm has built biometric technology to bring this data to the 1/3 of women with severe reproductive health symptoms. Their technology can monitor key metrics like volume, flow rate, cycle length and regularity to aid understanding of menstrual health.
Octiocor - Presenter: CMO/Founder - Martin Bennett
Octiocor's AutoOCT™ web-based platform is a fully automated artificial intelligence neural network-based image analysis system that was developed to identify and measure atherosclerosis from optical coherence tomography (OCT).
The software interprets intravascular coronary artery images and will provide real-time decision support for cardiologists and can be used to stratify patients based on risk enabling cardiologists to make better decisions to prevent future heart attacks.
Indegra Therapeutics - Presenter: Chair - Damian Marron
Founded by Richard Hatley and Simon Macdonald in 2022, Indegra Therapeutics is an integrin-based drug discovery platform company with a radically different approach to unlock effective treatments for multiple diseases, including cancer and autoimmune diseases. Its technology allows degradation of aberrant extracellular and membrane bound proteins with novel bifunctional molecules.
The extracellular proteome contains many disease targets which are largely untapped and Indegra’s mission is to identify first-in-class protein degrading molecules with oral potential and high specificity for diseased tissue, ultimately leading to new medicines for patients.
